Breast Cancer

The discovery points to a novel treatment target for shrinking brain tumors that arise secondary to breast cancer, according to the study authors.

Findings from the phase 3 ASCENT trial demonstrate a clinically meaningful 57% reduction in the risk of disease worsening or death for patients receiving sacituzumab govitecan.

Understanding breast cancer and which patients may be more vulnerable to long-term treatment effects and which patients may benefit most, can help oncologists design the best personalized neoadjuvant and adjuvant human epidermal growth factor receptor 2 (HER2)-targeted therapy.

Modifications include high rates of neoadjuvant endocrine chemotherapy, genomic assay testing on core biopsies, and delays in planned surgeries.

The study, conducted by investigators from the Breast Cancer Surveillance Coalition (BCSC), had an objective to quantify the impact of the COVID-19 pandemic on both breast cancer screening and diagnostic mammography services in the United States.

In April 2020, colonoscopy screenings declined from 15.1 per 10,000 beneficiaries to 0.9, a 95% difference.

The study also analyzed the relationship between ultra-processed food and drink products with 2 other cancer types.

The studies had a minimum follow-up period of 24 weeks and reported at least 1 event of breast cancer or benign breast neoplasm, which included 90,360 participants.

Electricity may slow the speed at which breast cancer cells spread through the body, and in some cases may stop them entirely, according to a new study published in Bioelectricity.

Low doses of propylparaben–a chemical preservative found in food, drugs, and cosmetics–can alter pregnancy-related changes in the breast in ways that may lessen the protection against breast cancer normally conveyed by pregnancy hormones.

Sodas have significantly high sugar levels and a lack of nutritional value, which may contribute to conditions that can lead to breast cancer.

The FDA announced that it will hold a public meeting of the Oncologic Drugs Advisory Committee from April 27 to 29 to address the indications granted accelerated approval for 6 therapies.

Debu Tripathy, MD, University of Texas, MD Anderson Cancer Center at Houston, discussed the basic requirements of personalizing therapy.

The investigators performed a retrospective review of 215 patients age 65 years and older with TNBC or HER2+ breast cancer who underwent mastectomy from 2005 to 2020 at a single institution.

This activity is supported by educational grants from Seagen Inc., Daiichi Sankyo, and AstraZeneca.

Study findings illustrate the need for better communication between health care providers and patients experiencing concerns during the pandemic.

As immunotherapies continue to show promise in more effectively combating several tumor types, many current strategies focus on ensuring the efficient delivery of active cytotoxic cells directly to tumors.

A deep learning model was found to support the identification of imaging biomarkers on screening mammograms, according to researchers at Massachusetts General Hospital.

Current cancer research focuses heavily on adjunct immunotherapy in combination with traditional chemotherapy.

Fractional CO2 laser therapy may offer a nonhormonal treatment to improve sexual function in survivors of breast cancer with genitourinary syndrome of menopause.

Data show that 1 in 5 men and women worldwide develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease, according to the study.

Women whose tumors responded to estrogen treatment were found to benefit from hormone therapy, whereas those whose tumors did not respond experienced worsening disease.

The guidelines recommend discontinuing routine mammograms for survivors with a life expectancy under 5 years, considering stopping screening for those with a 5- to 10-year life expectancy, and continuing mammography for those whose life expectancy is greater than 10 years.

Research highlights the need for cardiologists and cardio-oncologists to be involved in the treatment of men with breast cancer due to common risk factors and potential cardiotoxic effects of treatment.

During a study investigating therapeutics that target how RNA splicing activates antiviral immune pathways in triple-negative breast cancers, researchers observed that endogenous RNA in tumor cells that had been mis-spliced is able to mimic an RNA virus.